| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8077451d50e84d3e18431ed8b903518 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-685 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00 |
| filingDate |
2009-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2601f05e4c4a44816e3966fa011941
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef79e609344c88164092743fe6ff6c6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff060a4a259d4a2812ff2591fde6cef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a7833485382041e8025d5891b9ddadc |
| publicationDate |
2009-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009304586-A1 |
| titleOfInvention |
Chelating Agent Conjugated Alpha-MSH Peptide Derivatives, Preparation Method Thereof and Composition for Diagnosis and Treatment of Melanoma Comprising the Same as an Active Ingredient |
| abstract |
Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is α-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010113337-A1 |
| priorityDate |
2008-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |